Embassy Suites by Hilton Denver Downtown Floorplan
This meeting took place in 2022
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics (E2)
Organizer(s) Bridget Wagner, Neil O. Carragher, Jeremy Jenkins and Laura Kiessling
May 22—25, 2022
Embassy Suites by Hilton Denver Downtown • Denver, CO USA
Abstract Deadline: Mar 14, 2022
Scholarship Deadline: Mar 14, 2022
Discounted Registration Deadline: Mar 22, 2022
Sponsored by AbbVie Inc., BioLegend, Inc., Genmab A/S, Merck & Co., Inc. and PhenoVista Biosciences
Summary of Meeting:
PDD as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This meeting will bring together researchers performing or interested in phenotypic drug discovery (PDD) from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. The previous two PDD Keystone Symposia, in 2016 and 2019, were tremendously received, and we have determined that there is ample enthusiasm for hosting another Keystone Symposium on this evolving topic. Our goals in this meeting are to 1) share information and best practices in new PDD technologies, biological models, and human disease areas; 2) foster collaborative discussions across academia and industry; and 3) address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). We anticipate that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.
View Scholarships/Awards
PDD as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This meeting will bring together researchers performing or interested in phenotypic drug discovery (PDD) from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. The previous two PDD Keystone Symposia, in 2016 and 2019, were tremendously received, and we have determined that there is ample enthusiasm for hosting another Keystone Symposium on this evolving topic. Our goals in this meeting are to 1) share information and best practices in new PDD technologies, biological models, and human disease areas; 2) foster collaborative discussions across academia and industry; and 3) address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). We anticipate that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, May 22 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, May 25 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, May 26 in order to fully experience the meeting.
SUNDAY, MAY 22
MONDAY, MAY 23
TUESDAY, MAY 24
WEDNESDAY, MAY 25
THURSDAY, MAY 26
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, May 22 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, May 25 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, May 26 in order to fully experience the meeting.
SUNDAY, MAY 22
16:00—20:00
Arrival and Registration
Crystal Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
Crystal Foyer
07:00—08:00
Breakfast
At Individual Hotel
08:00—09:00
Welcome and Keynote Address (8am Start)
Crystal Ballroom
*
Bridget Wagner,
Broad Institute, USA
Session Chair
Session Chair
Anne E. Carpenter,
Broad Institute of Harvard and MIT, USA
Cell Painting Powers Next Generation Phenotypic Drug Discovery
Cell Painting Powers Next Generation Phenotypic Drug Discovery
09:00—11:00
Applications of Modern Computational Techniques to PDD (9am Start)
Crystal Ballroom
*
Paul A. Clemons,
Broad Institute of Harvard and MIT, USA
Session Chair
Session Chair
Ci Chu,
Insitro, USA
Machine Learning Driven TSC Disease Modeling and Reversion Screening in an iPSC Derived Disease Model
Machine Learning Driven TSC Disease Modeling and Reversion Screening in an iPSC Derived Disease Model
Coffee Break
*
Yolanda Chong,
Recursion Pharmaceuticals, USA
Integrating Imaging with Machine Learning in Phenotypic Screening
Integrating Imaging with Machine Learning in Phenotypic Screening
Christian Meyer,
University of Colorado Boulder, USA
A Consensus Framework for Calculating Drug Synergy in Phenotypic Assays
A Consensus Framework for Calculating Drug Synergy in Phenotypic Assays
Asako Tsubouchi,
ThinkCyte Inc, Japan
Short Talk: Novel Machine Vision-based Cytometry Approach for High-throughput Pooled Phenotypic CRISPR Screening
Short Talk: Novel Machine Vision-based Cytometry Approach for High-throughput Pooled Phenotypic CRISPR Screening
11:15—17:00
On Own for Lunch
11:15—13:00
Poster Setup
Crystal Ballroom
13:00—22:00
Poster Viewing
Crystal Ballroom
15:00—16:30
Workshop: AI Enabling of Phenotypic Drug Discovery (3pm Start)
Serena Silver,
Fulcrum Therapeutics, USA
Remote Presentation: Revolutionizing Drug Discovery for Genetically Defined Disease using Disease Relevant Cell Types and High-dimensional Phenotypic Datasets
Remote Presentation: Revolutionizing Drug Discovery for Genetically Defined Disease using Disease Relevant Cell Types and High-dimensional Phenotypic Datasets
Johannes Wilbertz,
Ksilink, France
Machine Learning-aided Multidimensional Phenotyping of Parkinson's Disease Patient Stem Cell-derived Midbrain Dopaminergic Neurons
Machine Learning-aided Multidimensional Phenotyping of Parkinson's Disease Patient Stem Cell-derived Midbrain Dopaminergic Neurons
Denise V. Barrault,
Exscientia AI Ltd., UK
XcellomicsTM: An AI-driven Phenomics Drug Discovery Collaboration
XcellomicsTM: An AI-driven Phenomics Drug Discovery Collaboration
*
Douglas Selinger,
Plex Research, USA
Plex: A Novel form of Artificial Intelligence (AI) for the Identification of Compound Targets and Mechanism of Action
Plex: A Novel form of Artificial Intelligence (AI) for the Identification of Compound Targets and Mechanism of Action
Gregory Way,
University of Colorado Anschutz, USA
Predicting Drug Polypharmacology from Cell Morphology Readouts using Variational Autoencoder Latent Space Arithmetic
Predicting Drug Polypharmacology from Cell Morphology Readouts using Variational Autoencoder Latent Space Arithmetic
Daniel Krentzel,
Institut Pasteur, France
Deep Learning for Antibiotic Target Identification from High-Throughput Images
Deep Learning for Antibiotic Target Identification from High-Throughput Images
16:30—17:00
Coffee Available
Crystal Foyer
17:00—19:00
Phenotypic Approaches to Tackling Infectious Disease (5pm Start)
Crystal Ballroom
*
Laura L. Kiessling,
Massachusetts Institute of Technology, USA
Bacterial Glycan Assembly: A New Approach to Antibiotics Discovery
Bacterial Glycan Assembly: A New Approach to Antibiotics Discovery
Jason K. Sello,
University of California, San Francisco, USA
Discovery of Novel Small Molecules to Target Tuberculosis
Discovery of Novel Small Molecules to Target Tuberculosis
*
Marc P. Windisch,
Institut Pasteur Korea, South Korea
Phenotypic Screening of FDA-Approved Drugs Using Middle East Respiratory Syndrome Coronavirus Identifies Potential Therapeutic Options for COVID-19
Phenotypic Screening of FDA-Approved Drugs Using Middle East Respiratory Syndrome Coronavirus Identifies Potential Therapeutic Options for COVID-19
Floriano P. Silva-Jr,
Fiocruz, Brazil
Short Talk: SchistoSPro: An Innovative and Cost-effective Platform to Identify New Drugs against Adult Schistosome Worms
Short Talk: SchistoSPro: An Innovative and Cost-effective Platform to Identify New Drugs against Adult Schistosome Worms
Brian Y. Feng,
Calico Labs, USA
Short Talk: Morphological Characterization of Antibiotic Combinations
Short Talk: Morphological Characterization of Antibiotic Combinations
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Crystal Foyer
19:30—22:00
Poster Session 1
Crystal Ballroom
07:00—08:00
Breakfast
At Individual Hotel
07:30—08:00
Poster Setup
Crystal Ballroom
08:00—19:00
Poster Viewing
Crystal Ballroom
08:00—11:00
Novel Chemistry to Enable PDD (8am Start)
Crystal Ballroom
Raphaël Rodriguez,
Institut Curie, France
Novel Chemical Tools to Discover Intracellular Targets
Novel Chemical Tools to Discover Intracellular Targets
Amit Choudhary,
Harvard Medical School, USA
Phosphorylation-inducing Chimeric Small Molecules
Phosphorylation-inducing Chimeric Small Molecules
Coffee Break
*
Susanne Müller-Knapp,
Structural Genomics Consortium - Frankfurt, Germany
Open-Source Chemical Probes for Understanding Cellular Phenotypes
Open-Source Chemical Probes for Understanding Cellular Phenotypes
*
Seung Bum Park,
Seoul National University, South Korea
Targeted Protein Upregulation Potentiates STING Agonist Immunotherapy
Targeted Protein Upregulation Potentiates STING Agonist Immunotherapy
Zita Hubler,
Case Western Reserve University School of Medicine, USA
Short Talk: Remyelinating Therapies and the Cholesterol Biosynthesis Pathway: An Unexpected Role for 8,9-unsaturated Sterols
Short Talk: Remyelinating Therapies and the Cholesterol Biosynthesis Pathway: An Unexpected Role for 8,9-unsaturated Sterols
Ctibor Škuta,
IMG CAS, Czech Republic
Short Talk: Probes & Drugs Portal in 2022: A Hub for the Integration of High-quality Bioactive Compound Sets
Short Talk: Probes & Drugs Portal in 2022: A Hub for the Integration of High-quality Bioactive Compound Sets
11:00—12:30
Lunch
Crystal Foyer
12:00—14:30
Poster Session 2
Crystal Ballroom
16:30—17:00
Coffee Available
Crystal Foyer
17:00—19:00
Innovative Cell and Animal Models to Advance PDD (5pm Start)
Crystal Ballroom
*
Laura L. Kiessling,
Massachusetts Institute of Technology, USA
Session Chair
Session Chair
*
Bridget Wagner,
Broad Institute, USA
A Human Pancreatic Islet Cell Culture System for Phenotypic Screening
A Human Pancreatic Islet Cell Culture System for Phenotypic Screening
Matthäus Mittasch,
Dewpoint Therapeutics GmbH, Germany
Assaying Small Molecule Partitioning into Biomolecular Condensates
Assaying Small Molecule Partitioning into Biomolecular Condensates
Emily G. Tippetts,
University of Utah, USA
Short Talk: Chemical Screening in Zebrafish Models of Leigh Syndrome
Short Talk: Chemical Screening in Zebrafish Models of Leigh Syndrome
Sietske Bakker,
Genmab, Netherlands
Short Talk: Quantification of T-cell Proliferation in High Throughput Screening
Short Talk: Quantification of T-cell Proliferation in High Throughput Screening
19:00—21:00
On Own for Dinner
07:00—08:00
Breakfast
At Individual Hotel
08:00—11:15
Systems Biology Approaches to Chemical Biology (8am Start)
Crystal Ballroom
Paul A. Clemons,
Broad Institute of Harvard and MIT, USA
Chemical Biology Applications of Pathway and Network Approaches to Human Disease
Chemical Biology Applications of Pathway and Network Approaches to Human Disease
Taran S. Gujral,
Fred Hutchinson Cancer Research Center, USA
Systems Pharmacology and Machine Learning Identifies Druggable Cancer Cell-stroma Interactions
Systems Pharmacology and Machine Learning Identifies Druggable Cancer Cell-stroma Interactions
Coffee Break
*
Jeremy Jenkins,
Novartis Institutes for BioMedical Research, USA
Systematic Assembly of a Chemogenetic Library and MOA Elucidation
Systematic Assembly of a Chemogenetic Library and MOA Elucidation
Sujatha M. Gopalakrishnan,
AbbVie, Inc., USA
Small Molecule Phenotypic Screening Efforts at AbbVie to Identify Novel Biology and Druggable Targets
Small Molecule Phenotypic Screening Efforts at AbbVie to Identify Novel Biology and Druggable Targets
Jessica Lacoste,
University of Toronto, Canada
Short Talk: Pervasive Mislocalization of Pathogenic Coding Variants Underlying Human Diseases
Short Talk: Pervasive Mislocalization of Pathogenic Coding Variants Underlying Human Diseases
*
Jayme L. Dahlin,
NCATS, USA
Short Talk: High-content Biological Annotation of Chemical Space with the NCATS ASPIRE Initiative
Short Talk: High-content Biological Annotation of Chemical Space with the NCATS ASPIRE Initiative
Alex Federation,
Talus Bio, USA
Short Talk: Profiling the DNA Regulome to Discover Transcription Factors Inhibitors
Short Talk: Profiling the DNA Regulome to Discover Transcription Factors Inhibitors
11:15—17:00
On Own for Lunch
15:00—16:30
Career Roundtable
Crystal Ballroom
Jason K. Sello,
University of California, San Francisco, USA
Deborah M. Rothman,
Merck & Co. Inc, USA
16:30—17:00
Coffee Available
Crystal Foyer
17:00—18:45
Advances in Approaches to Understand Mechanism of Action (5pm Start)
Crystal Ballroom
*
Neil O. Carragher,
University of Edinburgh, UK
Accelerating PDD through Multiparametric High Content Imaging and Pathway Profiling across Genetically Distinct Cell Panels
Accelerating PDD through Multiparametric High Content Imaging and Pathway Profiling across Genetically Distinct Cell Panels
*
John G. Moffat,
Genentech, Inc., USA
You Can't Always Get What You Want, But... : From Pathway Screening to Target Identification
You Can't Always Get What You Want, But... : From Pathway Screening to Target Identification
Nigel Beaton,
Biognosys, Switzerland
Short Talk: Limited Proteolysis as a Proteomics Tool for Target Deconvolution and Mechanistic Insights – A Test Case
Short Talk: Limited Proteolysis as a Proteomics Tool for Target Deconvolution and Mechanistic Insights – A Test Case
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (6:45pm Start)
Crystal Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Crystal Foyer
08:00—08:00
Departure
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
We gratefully acknowledge additional support from these exhibitors at this conference:
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org, Phone:+1 970-262-1179 |